NKX2-1-AS1 promotes the lymphangiogenesis of lung adenocarcinoma through regulation of ERG-mediated FABP4
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Long non-coding RNA NKX2-1-AS1 promotes lung adenocarcinoma (LUAD) cell growth and lymphatic spread by regulating FABP4 transcription via ERG, contributing to lymphangiogenesis.
Area Of Science
- Oncology
- Molecular Biology
- Cell Biology
Background
- Lymphatic metastasis is a significant challenge in lung adenocarcinoma (LUAD) treatment.
- Understanding the molecular mechanisms driving lymphangiogenesis in LUAD is crucial for developing targeted therapies.
Purpose Of The Study
- To investigate the role of long non-coding RNA NKX2-1-AS1 in lymphangiogenesis in LUAD.
- To elucidate the underlying molecular mechanisms involving ERG and fatty acid binding protein 4 (FABP4).
Main Methods
- Analysis of NKX2-1-AS1 expression in clinical LUAD tissues.
- In vitro gain- and loss-of-function assays in LUAD cell lines (H441, H661).
- Assessment of human lymphatic endothelial cell (HLEC) tube formation.
- Luciferase and RNA immunoprecipitation (RIP) assays to validate molecular interactions.
Main Results
- NKX2-1-AS1 was highly expressed in LUAD tissues.
- Silencing NKX2-1-AS1 reduced LUAD cell proliferation, migration, and lymphangiogenesis markers (LYVE-1, VEGF-C, VEGFR3, VEGF-A, VEGFR2, CCR7).
- NKX2-1-AS1 was found to regulate FABP4 transcription by interacting with ERG; FABP4 overexpression counteracted the inhibitory effects of NKX2-1-AS1 silencing.
Conclusions
- NKX2-1-AS1 promotes LUAD cell proliferation and migration.
- NKX2-1-AS1 facilitates lymphangiogenesis by regulating FABP4 transcription through ERG.
- Targeting NKX2-1-AS1 may offer a therapeutic strategy for inhibiting LUAD lymphatic metastasis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
